BriaCell Therapeutics’ Phase 3 Bria-IMT trial in metastatic breast cancer (Bria-ABC) is highlighted by Nature Medicine in its Year In Review as one of eleven clinical trials expected to shape medicine in 2026.

The interim overall survival analysis uses a primary endpoint comparing Bria-IMT plus a checkpoint inhibitor against physician’s choice therapy, with Bria-IMT carrying FDA Fast Track designation.

Dr. Sara A. Hurvitz notes that BRIA-ABC is inclusive of all breast cancer subtypes and patients with brain metastases, using a real-world comparator arm to enhance clinical relevance.

Trial details include the ClinicalTrials.gov identifier NCT06072612, with anticipated data milestones and standard forward-looking statements and risk disclosures.

The article cites Nature Medicine’s coverage of Eleven clinical trials that will shape medicine in 2026 (Nat Med, 2025), and includes forward-looking statements about risks and uncertainties in clinical development and data reporting timelines.

The report adds context on market and investor considerations, including enrollment progress, timing of interim readouts, and potential implications for regulatory approvals and pricing in metastatic breast cancer.

BriaCell expects to report top-line data in the first half of 2026 (H1-2026).

The trial’s FDA Fast Track designation underscores potential for expedited development and review, with top-line data anticipated as early as H1-2026.